FDA, FTC warn companies for selling illegal, unapproved opioid cessation products using deceptive claims

News provided by

Jan 24, 2018, 09:53 ET

SILVER SPRING, Md., Jan. 24, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and the Federal Trade Commission today posted joint warning letters to the marketers and distributors of 12 opioid cessation products, for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal.

"The FDA is increasingly concerned with the proliferation of products claiming to treat or cure serious diseases like opioid addiction and withdrawal," said FDA Commissioner Scott Gottlieb, M.D. "People who are addicted to opioids should have access to safe and effective treatments and not be victimized by unscrupulous vendors who are trying to capitalize on the opioid epidemic by taking advantage of consumers and selling products with baseless claims. We'll continue to work with our partners at the FTC to step up our actions against unapproved products being marketed for the treatment of opioid addiction and withdrawal."

Health fraud scams like these can pose serious health risks. These products have not been demonstrated to be safe or effective and may keep some patients from seeking appropriate, FDA-approved therapies. Selling these unapproved products with claims that they can treat opioid addiction and withdrawal is a violation of the Federal Food, Drug, and Cosmetic Act. Making unsubstantiated therapeutic claims is also a violation of the Federal Trade Commission Act, which prohibits deceptive advertising.

"Opioid addiction is a serious health epidemic that affects millions of Americans," said Acting FTC Chairman Maureen K. Ohlhausen. "Individuals and their loved ones who struggle with this disease need real help, not unproven treatments. We will continue to work together with the FDA to address this important issue."

Reducing the number of Americans who are addicted to opioids and cutting the rate of new addiction is one of the Administration's highest priorities. This work includes promoting more widespread innovation and access to opioid addiction treatments for the more than 2 million of Americans with an opioid use disorder. The FDA is taking new steps to make safe and effective medication assisted treatments (MAT) available to those who suffer from opioid use disorder and to reduce the stigma that is sometimes associated with use of these therapies. Using products with unsubstantiated claims may prevent those addicted to opioids from seeking approved treatments that have been demonstrated to be safe and effective, delay their path to recovery, and put them at greater risk of death. In fact, patients receiving FDA-approved medication-assisted treatment cut their risk of death in half, according to the Substance Abuse and Mental Health Services Administration (SAMHSA).

The FDA and FTC issued joint warning letters to 11 companies for their products: Opiate Freedom Center ("Opiate Freedom 5-Pack"), U4Life, LLC ("Mitadone"), CalmSupport, LLC ("CalmSupport"), TaperAid ("TaperAid" & "TaperAid Complete"), Medicus Holistic Alternatives LLC ("Natracet"), NutraCore Health Products, LLC ("Opiate Detox Pro"), Healthy Healing, LLC ("Withdrawal Support"), Soothedrawal, Inc. ("Soothedrawal"), Choice Detox Center, Inc. ("Nofeel"), GUNA, Inc. ("GUNA-ADDICT 1"), and King Bio, Inc. ("AddictaPlex").

The FTC sent four additional warning letters to other marketers of opioid cessation products.

All of the companies use online platforms to make illegal claims about their products' ability to cure, treat, or prevent a disease. Examples of claims made include:

"#1 Selling Opiate Withdrawal Brand"
"Imagine a life without the irritability, cravings, restlessness, excitability, exhaustion and discomfort associated with the nightmare of addiction and withdrawal symptoms"
"Safe and effective natural supplements that work to ease many physical symptoms of opiate withdrawal"
"Break the pain killer habit"
"Relieve Your Symptoms…addiction, withdrawal, cravings."

The FDA and FTC have requested responses from each of the companies within 15 working days. The companies are directed to inform each agency of the specific actions taken to address each agency's concerns. The warning letters also state that failure to correct violations may result in law enforcement action such as seizure or injunction.

Also today, the FTC, in coordination with SAMHSA of the U.S. Department of Health and Human Services (HHS), issued a fact sheet to help consumers get real help for opioid addiction or withdrawal, while avoiding products that promise but do not deliver help. The fact sheet has tips that consumers and health practitioners alike can share with those considering help for opioid addiction or withdrawal.

Health care professionals and consumers are encouraged to report any adverse events related to these products to the FDA's MedWatch Adverse Event Reporting program. To file a report, use the MedWatch Online Voluntary Reporting Form. The completed form can be submitted online or via fax to 800-FDA-0178.

The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow the FTC on Twitter, read FTC's blogs and subscribe to press releases for the latest FTC news and resources.

Media Inquiries: Mitchell Katz, 202-326-2161, [email protected] ; Lyndsay Meyer, 240-402-5345, [email protected]
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration